Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lundbeck Looks To Pipeline As Generic Competition Hits

Executive Summary

Lundbeck highlighted R&D and the strong growth of four strategic products in the first half, as revenues were hit by generic competitors to top-selling products.

You may also be interested in...



Lundbeck Boosts US R&D Capability With $400m Abide Theraputics Bid

Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.

Pressure Builds On Lundbeck After Rexulti Fails In Bipolar I Manic Episodes

Rexulti failed in two Phase III trials to statistically separate from placebo in bipolar I manic episodes.

The Darkest Hour Is After DAYBREAK For Lundbeck’s New Antipsychotic

The first Phase III study for Lundbeck’s novel antipsychotic flops leaving the Danish company shares down by 25% as investors wonder what’s left in the pipeline.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125707

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel